<DOC>
	<DOCNO>NCT00788112</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth tumor cell block enzymes need cell growth . PURPOSE : This clinical trial study well vorinostat work treat woman ductal carcinoma situ breast .</brief_summary>
	<brief_title>Vorinostat Treating Women With Ductal Carcinoma Situ Breast</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate vivo molecular biological effect vorinostat analyze change proliferation apoptosis , histone acetylation , HDAC protein expression woman ductal carcinoma situ breast . OUTLINE : Patients receive oral vorinostat twice day 3 day absence unacceptable toxicity . Patients undergo lumpectomy mastectomy 2 hour last dose vorinostat . Blood tissue sample collect baseline surgery biomarker laboratory study . Samples analyze immunohistochemistry Ki-67 , HDAC1 HDAC6 protein expression , histone H4 α-tubulin acetylation . After completion study therapy , patient follow 1 month every 6 month 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ( core biopsy ) ductal carcinoma situ Stage 0 disease Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Potassium magnesium level normal Prothrombin time INR ≤ 1.5 time upper limit normal ( ULN ) ( unless patient receive therapeutic anticoagulation ) Partial thromboplastin time ≤ 1.2 time ULN ( unless patient receive therapeutic anticoagulation ) Serum creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective barrier method contraception No known psychiatric substance abuse disorder would preclude cooperation study requirement No active hepatitis A , B , C infection No active HIV infection No active infection No malignancy within past 5 year No condition would interfere absorption intake vorinostat No history current evidence condition laboratory abnormality would confound study result , interfere patient 's participation full duration study , would best interest patient participate PRIOR CONCURRENT THERAPY : More 2 week since prior IV antibiotic , antiviral , antifungals No prior gastrointestinal surgery procedure would interfere absorption intake vorinostat No prior concurrent therapy HDAC inhibitor , include valproic acid No prior treatment investigational agent No concurrent systemic steroids No concurrent anticancer chemotherapy , radiotherapy , biological therapy , investigational therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>